Shari S Rogal1,2, Peng Yan3, David Rimland4,5, Vincent Lo Re6, Hind Al-Rowais7, Linda Fried3,8, Adeel A Butt3,8,9,10. 1. Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, USA. rogalss@upmc.edu. 2. Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. rogalss@upmc.edu. 3. Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, University Drive (151C), Pittsburgh, PA, 15240, USA. 4. Atlanta VA Medical Center, Decatur, GA, USA. 5. Emory University School of Medicine, Atlanta, GA, USA. 6. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 7. Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA. 8. School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 9. Hamad Medical Corporation, Doha, Qatar. 10. Hamad Healthcare Quality Institute, Doha, Qatar.
Abstract
BACKGROUND AND AIMS: We aimed to assess the incidence and progression of chronic kidney disease (CKD) following hepatitis C virus (HCV) seroconversion. METHODS: This retrospective cohort study included Veterans with a confirmed HCV seroconversion between 2001 and 2014 and Veterans with negative HCV testing over the same time period. The outcomes included development of advanced CKD (eGFR < 60 mL/min/1.73 m(2) on two separate occasions at least 90 days apart, plus a ≥ 10 mL/min/1.73 m(2) decline from baseline) and progressive CKD (decline in eGFR of ≥ 30 mL/min/1.73 m(2) from baseline). Multivariable Cox proportional hazards models were used to evaluate the association between HCV and incident advanced and progressive CKD. RESULTS: The final cohort consisted of 71,528 Veterans, including 2589 with recently seroconverted HCV. Over a mean follow-up of 6 years, 36% of patients with and 31% without HCV developed advanced CKD (p < 0.001), and 35% of patients with vs. 26% without HCV developed progressive CKD (p < 0.001). After controlling for traditional risk factors, recently seroconverted HCV+ patients were significantly less likely to develop advanced CKD (HR 0.86; 95% CI 0.79, 0.92), and HCV status was not significantly associated with progressive CKD (HR 0.93; 95% CI 0.86, 1.00). Factors associated with developing advanced and progressive CKD included older age, female sex, diabetes, hypertension, development of cirrhosis, and substance abuse. CONCLUSIONS: In this cohort of newly infected US Veterans, HCV infection was associated with decreased incidence of advanced and unchanged risk of progressive CKD, suggesting a larger role for traditional risk factors in the development of CKD after HCV seroconversion.
BACKGROUND AND AIMS: We aimed to assess the incidence and progression of chronic kidney disease (CKD) following hepatitis C virus (HCV) seroconversion. METHODS: This retrospective cohort study included Veterans with a confirmed HCV seroconversion between 2001 and 2014 and Veterans with negative HCV testing over the same time period. The outcomes included development of advanced CKD (eGFR < 60 mL/min/1.73 m(2) on two separate occasions at least 90 days apart, plus a ≥ 10 mL/min/1.73 m(2) decline from baseline) and progressive CKD (decline in eGFR of ≥ 30 mL/min/1.73 m(2) from baseline). Multivariable Cox proportional hazards models were used to evaluate the association between HCV and incident advanced and progressive CKD. RESULTS: The final cohort consisted of 71,528 Veterans, including 2589 with recently seroconverted HCV. Over a mean follow-up of 6 years, 36% of patients with and 31% without HCV developed advanced CKD (p < 0.001), and 35% of patients with vs. 26% without HCV developed progressive CKD (p < 0.001). After controlling for traditional risk factors, recently seroconverted HCV+ patients were significantly less likely to develop advanced CKD (HR 0.86; 95% CI 0.79, 0.92), and HCV status was not significantly associated with progressive CKD (HR 0.93; 95% CI 0.86, 1.00). Factors associated with developing advanced and progressive CKD included older age, female sex, diabetes, hypertension, development of cirrhosis, and substance abuse. CONCLUSIONS: In this cohort of newly infected US Veterans, HCV infection was associated with decreased incidence of advanced and unchanged risk of progressive CKD, suggesting a larger role for traditional risk factors in the development of CKD after HCV seroconversion.
Authors: Eva Cediel; Beatriz Vázquez-Cruz; Josefa Navarro-Cid; Natalia de las Heras; David Sanz-Rosa; Victoria Cachofeiro; Vicente Lahera Journal: Kidney Int Suppl Date: 2002-12 Impact factor: 10.545
Authors: Vincent Lo Re; Joseph K Lim; Matthew Bidwell Goetz; Janet Tate; Harini Bathulapalli; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Farah Kidwai; Cynthia Brandt; Zachariah Dorey-Stein; K Rajender Reddy; Amy C Justice Journal: Pharmacoepidemiol Drug Saf Date: 2011-05-27 Impact factor: 2.890
Authors: Norah J Shire; Marepalli B Rao; Paul Succop; C Ralph Buncher; Janet A Andersen; Adeel A Butt; Raymond T Chung; Kenneth E Sherman Journal: Clin Gastroenterol Hepatol Date: 2008-12-25 Impact factor: 11.382
Authors: Essam F Elsayed; Mark J Sarnak; Hocine Tighiouart; John L Griffith; Tobias Kurth; Deeb N Salem; Andrew S Levey; Daniel E Weiner Journal: Am J Kidney Dis Date: 2008-05-29 Impact factor: 8.860
Authors: Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego Journal: Intern Emerg Med Date: 2018-09-25 Impact factor: 3.397
Authors: Sara Yee Tartof; Jin-Wen Hsu; Rong Wei; Kevin B Rubenstein; Haihong Hu; Jean Marie Arduino; Michael Horberg; Stephen F Derose; Lei Qian; Carla V Rodriguez Journal: Clin J Am Soc Nephrol Date: 2018-09-21 Impact factor: 8.237
Authors: Adeel A Butt; Peng Yan; Kara W Chew; Judith Currier; Kathleen Corey; Raymond T Chung; Ashfaq Shuaib; Abdul-Badi Abou-Samra; Javed Butler; Matthew S Freiberg Journal: Clin Infect Dis Date: 2017-08-15 Impact factor: 9.079